NRX Total Liab from 2010 to 2024
| NRXP Stock | USD 1.21 0.01 0.82% |
Total Liabilities | First Reported 2017-09-30 | Previous Quarter 23.7 M | Current Value 23.3 M | Quarterly Volatility 15.9 M |
Check NRX Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRX Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 372.8 K, Interest Expense of 114 K or Selling General Administrative of 20.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRX financial statements analysis is a perfect complement when working with NRX Pharmaceuticals Valuation or Volatility modules.
NRX | Total Liab |
Latest NRX Pharmaceuticals' Total Liab Growth Pattern
Below is the plot of the Total Liab of NRX Pharmaceuticals over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. NRX Pharmaceuticals' Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NRX Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
NRX Total Liab Regression Statistics
| Arithmetic Mean | 7,758,906 | |
| Geometric Mean | 825,578 | |
| Coefficient Of Variation | 167.98 | |
| Mean Deviation | 9,734,944 | |
| Median | 93,171 | |
| Standard Deviation | 13,033,178 | |
| Sample Variance | 169.9T | |
| Range | 46.6M | |
| R-Value | 0.62 | |
| Mean Square Error | 112T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | 1,814,158 | |
| Total Sum of Squares | 2378.1T |
NRX Total Liab History
About NRX Pharmaceuticals Financial Statements
NRX Pharmaceuticals shareholders use historical fundamental indicators, such as Total Liab, to determine how well the company is positioned to perform in the future. Although NRX Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in NRX Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on NRX Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 19 M | 15.7 M |
Pair Trading with NRX Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NRX Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NRX Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with NRX Stock
Moving against NRX Stock
| 0.77 | BMY | Bristol Myers Squibb | PairCorr |
| 0.76 | GILD | Gilead Sciences | PairCorr |
| 0.64 | ESPR | Esperion Therapeutics | PairCorr |
| 0.45 | DNA | Ginkgo Bioworks Holdings | PairCorr |
| 0.44 | FLGC | Flora Growth Corp | PairCorr |
The ability to find closely correlated positions to NRX Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NRX Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NRX Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NRX Pharmaceuticals to buy it.
The correlation of NRX Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NRX Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NRX Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NRX Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.